FDA approves first drug for treating agitation in Alzheimer’s patients

The latest stories trending on MedCity News.

Editor's Pick

Top Story FDA Approves First Drug for Treating Agitation in Alzheimer's Patients Rexulti, a drug for schizophrenia and depression, now has an additional approval for treating agitation in Alzheimer's disease patients. The FDA decision makes the Otsuka Pharmaceutical and Lundbeck product the first drug approved for this indication. Sponsored Content Webinar: Bringing eCommerce Best Practices to Healthcare to Attract and Retain Patients Presented by DexCare and MedCity News Don't miss this upcoming webinar on May 19th! The panelists will focus on how health systems are taking lessons learned from online retailers, and emerging technologies, to attract and convert consumers. Click to register today! Meet Jane Rho and Julianne Roseman in Chicago INVEST 2023 in Chicago May 22-24 is your opportunity to meet and connect with these investors: DaVita Venture Group and Plug and Play, plus innovative startups, additional investors and life sciences companies. Don't miss healthcare's greatest networking event of the year. Register Now

Featured News

Sobi Emerges as Savior for CTI Biopharma Cash Crunch With $1.7B M&A Deal Swedish Orphan Biovitrum is acquiring CTI Biopharma in a $1.7 billion deal centered on the biotech's commercialized drug for the blood cancer myelofibrosis. Sobi says the drug, Vonjo, complements one of its own assets approved for a different blood disorder. What 4 Employers Want From Health Vendors Employers are looking for more honesty from their potential health vendor partners. This was the topic of conversation during a Wednesday panel among benefit leaders at the Midwest Business Group on Health conference in Chicago. People Say Healthcare Check-in Should Be Like Airline Check-in. We Can Do So Much Better. Although the flight check-in process is quick and easy, it lacks the intelligence and personalization that would make it truly exceptional. When I say I am optimistic that we can do better in healthcare, it's because we are sitting on a wealth of data that lives, largely untapped, in the electronic health record FDA's Landmark Guidance on Decentralized Clinical Trials (DCTs) Signals a New Era of Patient-Centered Research With the FDA's acceptance and encouragement of decentralized trials, we can expect to see a continued shift towards remote trial conduct, virtual sites, and the use of innovative digital technologies. Without Change, Lifesaving HCT and Cell Therapies Will Be Out of Reach for Many Ending access and outcomes disparities in HCT and cell therapy will require a collaborative effort, from clinicians, associations and non-profit organizations in the hematology/oncology, HCT and cell therapy communities to policy makers and payers

Resources

Your HIPAA Compliance Checklist This one-page checklist quickly shows you everything that is required for you to become HIPAA compliant. Make sure you aren't missing a thing when it comes to your organization's compliance. Download Now

MedCity News • PO Box 901 • New York, NY unsubscribe